FoxO1 inhibitor also resulted in impaired signaling downstream of the crosslinked BCR, as evidenced by impaired pAktS473 and cMYC induction in primary CLL cells (fold-change, 0.4 for both, P < 0.01; Figure 4, F–H), similarly to mTOR inhibitor. The gene discussed is MYC; the disease is B-cell chronic lymphocytic leukemia.